小剂量血脂康和普伐他汀长期调脂作用的比较

小剂量血脂康和普伐他汀长期调脂作用的比较

徐成斌, 胡大一, 康丽萍, 田雅文, 高明明, 顼志敏, 靳三友, 马凤云, 马敏, 石湘芸, 张宝和, 龙南展, 李琳, 薛林, 张钧华, 陈秀丽, 戴呈祥

1.北京医科大学人民医院;
2.北京红十字会朝阳医院;
3.北京电力医院;
4.海军总医院;
5.北京医科大学第一人民医院;
6.空军北京医院

收稿日期:2000-08-12 修回日期:2000-10-06 出版日期:2000-12-15 发布日期:2000-12-15

Comparative Study of Relatively Long-term Therapy for Dyslipidemia with Low-dose Xuezhikang or Pravastatin in Chinese Patients

1. People's Hospital of Beijing Medical University, Beijing;
2. Chao Yang Hospital of Beijing Red Cross, Beijing;
3. Beijing Electrical Power Hospital, Beijing;
4. General Hospital of Marine Force, Beijing;
5. The First Hospital of Beijing Medical University, Beijing;
6. Airforce Beijing Hospital, Beijing

Received:2000-08-12 Revised:2000-10-06 Online:2000-12-15 Published:2000-12-15

摘要/Abstract

摘要： 目的: 观察小剂量血脂康、普伐他汀对高血脂病人的长期调脂作用。方法: 多中心, 195例高血脂病人, 分血脂康组每晚睡前口服血脂康2粒(含他汀类物质6mg)与普伐他汀组(每晚睡前口服5mg)治疗6个月, 比较治疗前、后血脂水平变化及两组间差异, 用方差分析法检验及X2检验。结果: 血脂康与普伐他汀治疗6个月时, TC下降16%及17%, TG下降13%及15%, LDL下降23%及21%; HDL在血脂康组上升2%, 在普伐他汀组上升10%。两组均能有效降低LDL/HDL。两组间比较普伐他汀升HDL作用较血脂康稍好(P = 0.05)。两组TC、LDL、LDL/HDL下降均有统计学意义。两组TG下降及HDL升高无统计学意义, 血脂康及普伐他汀组降TC疗效分别为54.6%、68.4%; 升HDL疗效分别为49.1%、53.9%; 降TG为46.2%、40.8%。两组疗效差异均无显著性。两组均未见严重副作用。结论: 小剂量他汀类药物(如血脂康和普伐他汀)长期口服治疗成人血脂紊乱, 安全、有效。

关键词: 血脂康/治疗应用, 普伐他汀/治疗应用, 高脂血症

Abstract: Objective To compare the effects of low-dose Xuezhikang with that of Pravastatin for long-term therapy on Chinese patients with dyslipidemia. Methods One hundred and ninety-five cases from six hospitals in Beijing were studied by being randomly divided into two groups and given Xuezhikang 2 capsules QN and Pravastatin 5 mg QN respectively for 6 months. The levels of TC, TG, LDL-C and HDL-C in pre- and post-treatment for each group were analyzed. The differences between the two groups were compared using ANOVA. The efficacy-rates for lowering TC, TG and increasing HDL-C of each group were calculated according to "The Guidline to Clinical Drug Research" and the differences between the two groups were compared with X² test. Results Comparing with pre-treatment the TC decreased 16% and 17%, TG decreased 13% and 15%, LDL-C decreased 23% and 21%, HDL-C increased 2% and 10% after administering for 6 months in Xuezhikang and Pravastatin groups respectively. Both of the drugs could decrease LDL/HDL effectively as well. The decreases of TC, TG, LDL-C, and LDL/HDL were statistically significant in both groups comparing with pre-treatment, however, no significant differences were found between the two groups. But there was significant difference in the increases of HDL-C between two groups. The efficacy-rates of Xuezhikang and Pravastatin were 54.6% and 68.4% for TC, 49.1% and 53.9% for HDL-C, 46.2% and 40.8% for TG respectively. There were no significant differences between the two groups. No severe side effects were observed in the two groups. Conclusion Low-dose statin drugs (such as Xuezhikang and Pravastatin) administrated in relatively long-term are effective and safe for Chinese patients with dyslipidemia.

Key words: Xuezhikang/therapeutical, Xuezhikang/therapeutical, Pravastatin/therapeutical usage, Pravastatin/therapeutical usage, Hyperlipidemia, Hyperlipidemia

Supporting:

徐成斌, 胡大一, 康丽萍, 田雅文, 高明明, 顼志敏, 靳三友, 马凤云, 马敏, 石湘芸, 张宝和, 龙南展, 李琳, 薛林, 张钧华, 陈秀丽, 戴呈祥. 小剂量血脂康和普伐他汀长期调脂作用的比较[J]. .

Xu Chengbin, Hu Dayi, Kang Liping, Tian Yawen, Gao Mingming, Xu Zhimin, Jin Sanyou, Ma Fengyun, Ma Min, Shi Xiang yun, Zhang Baohe, Long Nanzhan, Li Lin, Xue Lin, Zhang Junhua, Chen Xiuli, Dai ChengXiang. Comparative Study of Relatively Long-term Therapy for Dyslipidemia with Low-dose Xuezhikang or Pravastatin in Chinese Patients[J]. .

[1]	闫焕, 王健, 付浩, 杨敏, 曲苗, 方志娥. 基于网络药理学探讨大柴胡汤治疗高脂血症的潜在作用靶点和机制[J]. 中国药学(英文版), 2023, 32(6): 446-459.
[2]	徐小妹, 李丽莎, 张亚敏, 卢雪花, 徐榕青, 吴双双, 林纬, 林文津. 基于转录组学技术研究泽泻汤对高脂血症大鼠的降脂作用机制[J]. 中国药学(英文版), 2021, 30(5): 409-420.
[3]	寇文镕, 陆宗良, 郭静萱, 李海燕, 薛士文, 林玉珍, 吴学思, 陈红. 血脂康用于治疗初期高脂血症[J]. , 2000, 9(4): 214-217.